Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

Completed · Phase 1

Conditions studied: Healthy

In brief

This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.

Key facts

Study ID

NCT01870986

Run by

Pfizer

People needed

210

Starts

2013-05-01

Expected to finish

2014-02-01

Last updated by the study team

2014-02-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female (non-childbearing potential). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse, ECG, and laboratory testing.

You may not qualify if…

• Evidence or history of clinically significant infectious, hematological, renal, endocrine, pulmonary gastrointestinal, cardiovascular, hepatic psychiatric, neurologic, autoimmune, or allergic disease.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Brussels, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.